{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lai SK"],"funding":["National Center for Advancing Translational Sciences","Eshelman Institute for Innovation, University of North Carolina at Chapel Hill","NCATS NIH HHS","NIAID NIH HHS","National Institutes of Health","David and Lucile Packard Foundation","National Science Foundation"],"pagination":["87-95"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7836766"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["329"],"pubmed_abstract":["COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic interventions. Due to their safety, specificity, and potential for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promising class of antiviral or anti-inflammatory agents. Herein, by analyzing prior efforts to advance antiviral mAbs for other acute respiratory infections (ARIs), we highlight the challenges faced by mAb-based immunotherapies for COVID-19. We present evidence supporting early intervention immediately following a positive diagnosis via inhaled delivery of mAbs with vibrating mesh nebulizers as a promising approach for the treatment of COVID-19."],"journal":["Journal of controlled release : official journal of the Controlled Release Society"],"pubmed_title":["Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19."],"pmcid":["PMC7836766"],"funding_grant_id":["R44 AI138728","UL1 TR002489","R43 AI149894","R43 AI155185","R44 AI141054"],"pubmed_authors":["Lai SK","McSweeney MD","Pickles RJ"],"additional_accession":[]},"is_claimable":false,"name":"Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19.","description":"COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic interventions. Due to their safety, specificity, and potential for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promising class of antiviral or anti-inflammatory agents. Herein, by analyzing prior efforts to advance antiviral mAbs for other acute respiratory infections (ARIs), we highlight the challenges faced by mAb-based immunotherapies for COVID-19. We present evidence supporting early intervention immediately following a positive diagnosis via inhaled delivery of mAbs with vibrating mesh nebulizers as a promising approach for the treatment of COVID-19.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2024-11-08T10:27:50.46Z","creation":"2021-02-21T04:11:22Z"},"accession":"S-EPMC7836766","cross_references":{"pubmed":["33276017"],"doi":["10.1016/j.jconrel.2020.11.057"]}}